Protalix BioTherapeutics Inc (PLX)
1.18
-0.03
(-2.48%)
USD |
NYAM |
Apr 25, 16:00
1.20
+0.02
(+1.69%)
Pre-Market: 20:00
Protalix BioTherapeutics Net Income (Quarterly): -6.044M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -6.044M |
| September 30, 2023 | -1.852M |
| June 30, 2023 | 19.34M |
| March 31, 2023 | -3.131M |
| December 31, 2022 | -3.74M |
| September 30, 2022 | -3.567M |
| June 30, 2022 | -5.334M |
| March 31, 2022 | -2.286M |
| December 31, 2021 | -6.667M |
| September 30, 2021 | -4.199M |
| June 30, 2021 | -11.24M |
| March 31, 2021 | -5.475M |
| December 31, 2020 | 0.397M |
| September 30, 2020 | -4.437M |
| June 30, 2020 | -4.15M |
| March 31, 2020 | 1.667M |
| December 31, 2019 | 0.291M |
| September 30, 2019 | -3.56M |
| June 30, 2019 | -7.743M |
| March 31, 2019 | -7.264M |
| December 31, 2018 | -5.434M |
| September 30, 2018 | -5.322M |
| June 30, 2018 | -8.462M |
| March 31, 2018 | -7.239M |
| December 31, 2017 | -13.30M |
| Date | Value |
|---|---|
| September 30, 2017 | -11.44M |
| June 30, 2017 | 0.45M |
| March 31, 2017 | -59.15M |
| December 31, 2016 | -2.624M |
| September 30, 2016 | -7.29M |
| June 30, 2016 | -10.85M |
| March 31, 2016 | -8.598M |
| December 31, 2015 | 72.90M |
| September 30, 2015 | -3.82M |
| June 30, 2015 | -5.071M |
| March 31, 2015 | -5.972M |
| December 31, 2014 | -8.469M |
| September 30, 2014 | -8.01M |
| June 30, 2014 | -6.119M |
| March 31, 2014 | -7.345M |
| December 31, 2013 | -10.88M |
| September 30, 2013 | -5.747M |
| June 30, 2013 | -6.837M |
| March 31, 2013 | -4.321M |
| December 31, 2012 | -9.877M |
| September 30, 2012 | -5.479M |
| June 30, 2012 | 9.642M |
| March 31, 2012 | -5.904M |
| December 31, 2011 | -8.913M |
| September 30, 2011 | -8.875M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-11.24M
Minimum
Jun 2021
19.34M
Maximum
Jun 2023
-2.723M
Average
-3.74M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Agenus Inc | -46.29M |
| InfuSystems Holdings Inc | 0.072M |
| Corbus Pharmaceuticals Holdings Inc | -8.021M |
| AIM ImmunoTech Inc | -12.58M |
| Armata Pharmaceuticals Inc | -19.85M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.49M |
| Total Expenses (Quarterly) | 16.10M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 61.89M |
| Gross Profit Margin (Quarterly) | 15.54% |
| Profit Margin (Quarterly) | -57.64% |
| Earnings Yield | 1.69% |
| Operating Earnings Yield | 11.40% |
| Normalized Earnings Yield | 1.695 |